Clinical trial

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

NCT01633112

Study summary

ClinicalTrials.gov

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record fingolimod Normalized identity: fingolimod View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record glatiramer acetate Normalized identity: glatiramer acetate View linked drug · Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2012-08-09

PhasePHASE3

Conditions

Relapsing-remitting Multiple Sclerosis (RRMS)unresolved

Interventions

fingolimodDRUG · verified · RxNorm: fingolimod

glatiramer acetateDRUG · verified · RxNorm: glatiramer acetate

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

St LouisMissouri, United States3 PhoenixArizona, United States3 NashvilleTennessee, United States2 SeattleWashington, United States2 ColumbusOhio, United States2 MontrealQuebec, Canada2 IndianapolisIndiana, United States2 Oklahoma CityOklahoma, United States2 DetroitMichigan, United States2 SantiagoChile2 Chihuahua CityMexico2 HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01633112 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.